Clinical Trials Browser

Phase 2 × Carcinoma, Hepatocellular × Indomethacin × Clear all

NCT07560566 2026-05-01

SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular